Other languages PepGen Inc.

Equities

PEPG

US7133171055

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
16.77 ^USD	-6.00%		+2.51%	+146.62%

06-11	PepGen Names Michelle Mellion as Chief Medical Officer	MT
06-11	Pepgen Inc. Announces Executive Promotions	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PepGen Names Michelle Mellion as Chief Medical Officer	06-11
Pepgen Inc. Announces Executive Promotions	06-11
PepGen Q1 Loss Narrows	05-15
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14
PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	03-13
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-06
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	03-04
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	02-20
PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	02-20
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	01-17
Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	01-08
Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1	12-18
PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors	11-15
PepGen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
PepGen Says FDA Lifted Clinical Hold on Application to Begin Myotonic Dystrophy Type 1 Phase 1 Study	23-10-12
PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-10-12
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences	23-09-06
PepGen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
PepGen Withdraws Timeline on Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-06-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PepGen Inc.

Equities

PEPG

US7133171055

Other languages

Filters